PTAFR and metabolic bone disorder: In contrast, PTAFR deficiency or the use of PTAFR antagonists significantly reduces bone loss in ovariectomised mice, suggesting that PTAFR acts as a bridge connecting inflammation and bone metabolic disorders [86].